The abnormal expression of breast cancer-specific gene 1 (BCSG1) in malignant mammary epithelial cells is highly associated with the development and progression of breast cancer. A series of in vitro and in vivo studies performed in our laboratory and others have demonstrated that BCSG1 expression significantly stimulates proliferation, invasion, and metastasis of breast cancer cells. However, currently little is known about how BCSG1 exerts its oncogenic functions. To elucidate the cellular mechanisms underlying the effects of BCSG1 in breast cancer cells, we used a yeast two-hybrid system to screen for proteins that could associate with BCSG1. Through this screening, we identified the mitotic checkpoint protein BubR1 as a novel binding partner of BCSG1. The specific association of BCSG1 with BubR1 in breast cancer cells was demonstrated by immunoprecipitation and GST pull-down assays. Intriguingly, experiments conducted in four different cell lines all showed that exogenous expressions of BCSG1 consistently reduce the cellular levels of the BubR1 protein without affecting BubR1 mRNA expression. The tendency of endogenous BCSG1 expression coinciding with lower BubR1 protein levels was also observed in seven out of eight breast cancer cell lines. We further showed that the reducing effect of BCSG1 on BubR1 protein expression could be prevented by treating BCSG1-transfected cells with MG-132, a selective 26S proteasome inhibitor, implying that the proteasome machinery may be involved in the BCSG1-induced reduction of the BubR1 protein. Accompanied with a reduction of BubR1 protein level, BCSG1 expression resulted in multinucleation of breast cancer cells upon treatment with spindle inhibitor nocodazole, indicating an impaired mitotic checkpoint. Taken together, our novel findings suggest that BCSG1 may accelerate the progression of breast cancer at least in part by compromising the mitotic checkpoint control through inactivation of BubR1.
We have reported that aldosterone is synthesized and cytochrome P450aldo mRNA exists in the vasculature. To clarify the pathophysiological role of vascular aldosterone in hypertension, we compared aldosterone production in the mesenteric arteries of stroke-prone spontaneously hypertensive rats (SHRSP) with that in Wistar-Kyoto rats (WKY). The expressions of mRNA of cytochrome P450aldo, mineralocorticoid receptor, and alpha 1, Na,K-ATPase in the mesenteric arteries were compared between the two groups. Aldosterone concentration in the perfusate of the vasculature was measured by radioimmunoassay after purification with high-performance liquid chromatography. Cytochrome P450aldo and mineralocorticoid receptor mRNA levels were quantified by Southern blot analysis of the products of reverse-transcribed polymerase chain reaction. Levels of alpha 1 Na,K-ATPase mRNA were measured by Northern blot analysis. Vascular aldosterone and cytochrome P450aldo mRNA levels of 2-week-old SHRSP were significantly increased compared with those of age-matched WKY. However, vascular aldosterone in 4- and 9-week-old SHRSP did not differ from that in age-matched WKY. Expression levels of mineralocorticoid receptor mRNA in the vasculature of 4- and 9-week-old SHRSP were significantly increased compared with those in age-matched WKY. Concentrations of vascular alpha 1 Na,K-ATPase mRNA of 2-, 4-, and 9-week-old SHRSP also were significantly higher than those in age-matched WKY. These results suggest that vascular aldosterone contributes to the pathophysiology of hypertension in SHRSP in the early stage.
The conversion of heterosubstituted methanes, such as methyl alcohol, dimethyl ether, methyl mercaptan, dimethyl sulfide, methylamines, and methyl halides, to ethylene and hydrocarbons derived thereof takes place over bifunctional acidic-basic-supported transition-metal oxide or oxyhalide catalysts, such as tungsten oxide supported on alumina, between 300 and 350 °C. The conversion of methyl alcohol starts with bimolecular dehydration to dimethyl ether followed by acid-catalyzed transmethylation giving trimethyloxonium ion (or related catalyst-bound methyloxonium ion). The trimethyloxonium ion then undergoes base-induced deprotonation forming a catalyst surface-bound methylenedimethyloxonium ylide. Intermolecular methylation of the ylide, indicated by experiments using singly 13C-labeled dimethyl ether, gives methylethyloxonium ion thus providing the crucial first C-C bond. No intramolecular Steven's-type rearrangement takes place, and methyl ethyl ether is not a significant intermediate as also shown in experiments comparing the products formed from reacting CD3OCH2CH3 under similar conditions. The ethyloxonium ion readily undergoes ß-elimination forming ethylene. Initialy formed ethylene subsequently can undergo further reaction with the ylide giving via cyclopropane propylene or it can undergo more complex alkylation/oligomerization/cracking reactions giving a mixture of alkenes, alkanes and via cyclization-dehydrogenation aromatics. The complexity of these processes was shown by reacting ethylene itself, as well as 13CH3OH and ethylene, under conditions of the condensation reaction. It is also necessary to differentiate initially formed ethylene via direct C¡ -* C2 conversion from that formed in secondary processes together with higher condensation products. The conversion of methyl mercaptan (dimethyl sulfide), methyl halides, and methylamines to ethylene follows similar onium ylide pathways.
Aberrant expressions of the neuronal protein synuclein gamma (SNCG) in malignant mammary epithelial cells are strongly associated with the progression of breast cancer. SNCG is not expressed in normal breast tissues but abundantly expressed in a high percentage of invasive and metastatic breast carcinomas. Several studies have demonstrated that SNCG expression significantly stimulates proliferation, invasion, and metastasis of breast cancer cells. To elucidate the molecular and cellular mechanisms underlying the tumorigenic functions of SNCG, we investigated the effects of SNCG expression on the mitotic checkpoint function of breast cancer cells. By conducting several different lines of investigations, we now demonstrate that SNCG expression in breast cancer cells overrides the mitotic checkpoint control and confers the cellular resistance to anti-microtubule drug-caused apoptosis. We further show that the inhibitory effects of SNCG on mitotic checkpoint can be overthrown by enforced overexpression of the mitotic checkpoint protein BubR1 in SNCG-expressing cells. These new findings combined with our previous observation that SNCG intracellularly associates with BubR1 together suggest that SNCG expression compromises the mitotic checkpoint control by inhibition of the normal function of BubR1, thereby promoting genetic instability. Genetic instability is recognized as an important contributing factor in tumorigenesis. Hence, our studies gain insight into the mechanisms whereby SNCG expression advances breast cancer disease progression and fasters tumor metastasis.
Mineralocorticoids have been suggested to act on blood vessels, leading to increased vasoreactivity and peripheral resistance. Aldosterone is synthesized locally in blood vessels and participates in the hypertrophy of vascular smooth muscle cells. In this study we examined the effects of angiotensin II (ANG II), potassium, and ACTH on the production of aldosterone, the activity of aldosterone synthase, and the expression of CYP11B2 and CYP11B1 messenger ribonucleic acid (mRNA) in cultured human vascular endothelial cells. Human vascular endothelial cells were incubated with ANG II, potassium, or ACTH with or without [14C]deoxycorticosterone ([14C]DOC). Incubation medium was collected, and chromatography was preformed in a reverse phase high performance liquid chromatography system. The concentration of aldosterone in the incubation medium was measured using RIA after separation with the high performance liquid chromatography system. The activity of aldosterone synthase was estimated by the conversion of [14C]DOC to [14C]aldosterone. The levels of CYP11B2 and CYP11B1 mRNA were determined by competitive PCR. ANG II, potassium, and ACTH increased the production levels of aldosterone in a dose-dependent fashion. Both ANG II and potassium increased the conversion of [14C]DOC to [14C]aldosterone, but ACTH did not significantly increase the conversion. Both ANG II and potassium increased the concentration of CYP11B2 mRNA, but not that of CYP11B1 mRNA. Tumor necrosis factor reduced ANG II- and potassium-induced aldosterone synthesis and CYP11B2 mRNA levels. ACTH did not influence the expression of CYP11B2 mRNA. These results suggest that vascular aldosterone synthase is controlled by ANG II and potassium at the transcriptional level.
Abstract-Tacrolimus (FK 506) is a powerful, widely used immunosuppressant. The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity. To clarify the mechanisms of FK 506 -induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels. In addition, the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506 -induced hypertension in rats was studied. FK 506, 5 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 given for 4 weeks, elevated blood pressure from 102Ϯ13 to 152Ϯ15 mm Hg and increased the synthesis of ET-1 and the levels of ET-1 mRNA in the mesenteric artery (240% and 230%, respectively). Little change was observed in the expression of ECE-1 mRNA and CNP mRNA. FK 506 decreased eNOS activity and the levels of eNOS mRNA in the aorta (48% and 55%, respectively). The administration of FR 139317 (10 mg ⅐ kg Ϫ1 ⅐ d Ϫ1) prevented FK 506 -induced hypertension in rats. These results indicate that FK 506 may increase blood pressure not only by increasing ET-1 production but also by decreasing NO synthesis in the vasculature. 1,2 FK 506 is 10 to 100 times more potent than cyclosporin (CysA). 3 The nephrotoxic side effects of CysA and the development of hypertension observed during CysA treatment also seem to be characteristic side effects of FK 506. 4 The incidence of hypertension in previously normotensive liver or heart transplant recipients treated with CysA has been reported to be 80% to 90%.5 A lower incidence (50% to 70%) of hypertension in FK 506 -treated recipients has been reported. 6 Although renal dysfunction is usually also present in transplant recipients treated with CysA or FK 506, blood pressure elevations have been observed in the absence of detectable renal dysfunction. 7,8 The exact mechanism of FK 506 -induced hypertension is unclear, but several researchers have suggested that the primary pathogenic mechanism may be vascular. 9 We have reported that CysA and FK 506 both increased the synthesis of endothelin-1 (ET-1) in cultured vascular endothelial cells. 10The natriuretic peptides organize a family of 3 distinct peptides (atrial natriuretic peptide [ANP], brain natriuretic peptide [BNP], and C-type natriuretic peptide [CNP]) and are involved in body fluid homeostasis and blood pressure control. CNP is reported to be synthesized in the vascular endothelial cells and to possess local effects of vascular tone and remodeling.11 Nitric oxide (NO) is synthesized from L-arginine by 2 enzymes. The generation of NO by constitutive, Ca 2ϩ -dependent NO synthase (NOS) from the vascular endothelium plays an important role in the homeostasis of the vascular system. Three isoforms of NOS have been cloned from rat brain (nNOS), vascular endothelium (eNOS), and inducible Ca 2ϩ -independent enzyme (iNOS). Vascular eNOS mainta...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.